Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500M. Source: BioSpace

With a priority review voucher in hand, Teva is expecting the FDA to rule on its new migraine treatment fremanezumab by June. Source: BioSpace

Arno Therapeutics is calling it quits. It sold off all its assets, with the final asset being the rights to Onapristone, which it sold to Context Biopharma. Source: BioSpace

Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades. Source: BioSpace

Next year should be enormously important for Canadian marijuana stocks, as the country moves forward with legalization of recreational marijuana. Source: BioSpace

Shares of Agile plunged more than 62 percent in early trading after the company announced this morning the FDA rejected its low-dose hormonal contraceptive patch called Twirla. Source: BioSpace

The parent company of JSR Life Sciences snapped up CRO Crown Bioscience International for $400M, the company announced this morning. Source: BioSpace

Under the seven-year nonexclusive licensing and supply agreement, Juno has obtained rights to use CTS Dynabeads CD3/CD28 magnetic beads as part of the clinical and commercial manufacturing processes for its…

Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and…

Five Prime and Zai Lab today announced an exclusive license agreement for FPA144 in Greater China and global strategic development collaboration. Source: BioSpace